Treatment of infantile hemangioma with topical imiquimod 5% cream
Hassan Seirafi, Amirhooshang Ehsani, Shabboo Jesri, Fatemeh Gholamali, Pedram Noormohammadpour
Contact Info: Pedram Noormohammadpour, MD Razi Hospital, Vahdat-e-Islami Square, Tehran, Iran Email: firstname.lastname@example.org
|Date Received: 2012 / Jul / 01
||Date Revised: 2012 / Jul / 01
||Date Accepted: 2012 / Oct / 20
Background: Infantile hemangioma is a congenital vascular
malformation. Although almost all cases are self-limiting, treatment
is sometimes necessary. According to previous studies, topical
imiquimod induces resolution of lesions with an acceptable safety
profile. The aim of the present study was to evaluate the effect of
this topical treatment on Iranian infantile hemangioma patients.
Method: Patients under two years of age with infantile hemangioma
who were not candidates for immediate systemic therapy with
steroids were selected if the lesions were not ulcerated. Topical
5% imiquimod was applied on the lesions for 16 weeks. All the
lesions were photographed before the commencement of the study
and at the end of the treatment. Photographs were compared by
two associate dermatology professors to evaluate the effect of
treatment using a visual analogue scale.
Result: A total of 15 patients including five males (33.3%) and
ten females (66.7%), with an age range of two to 18 months and
a mean age of 9.1 (± 6.3) months, were enrolled in the study.
The mean diameter of the lesions was 2.6 cm (± 1.8 cm). Nine
patients (60%) had moderate response and five patients (33.3%)
had good response while one patient had excellent response.
Complications were mild local irritation and pruritus.
Conclusion: It seems that topical imiquimod could be a suitable
option in the treatment of some infantile hemangioma lesions not
candidate for systemic treatment and/or other local measures
such as laser and intra lesional steroid or when other drugs are
useless or harmful..
Keywords: imiquimod, infantile hemangioma, topical treatment
Full Text |